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ABSTRAK 
TERAPI KOMBINASI UNTUK KAWALAN GLUKOSA YANG OPTIMA : 
KAJIAN RA WAK SECARA TERBUKA MEMBANDINGKAN 
ROSIGLITAZONE DENGAN KOMBINASI SULPHONYLUREAS DAN 
METFORMIN DI DALAM PESAKIT DIABETES 
Latar bela~ang 
Seperti yang telah diketahui, untuk mencapai tahap glukosa yang di ingini dalam 
perawatan diabetes adalah bukan perkara mudah. Kombinasi beberapa ubat adalah di 
perlukan pada kebanyakan pesakit. Kombinasi ubat yang sering digunakan melibatkan 
perembes insulin dan ubat yang mengurangkan rintangan insulin. Penggunaan duajenis 
ubat yang mengurangkan rintangan insulin tetapi dengan mekanisma kerja yang 
berbeza mungkin boleh memberikan kawalan glukosa yang lebih optima. Dengan 
menambahkan thiazolidindion mungkin membolehkan pencapaian tahap glukosa yang 
lebih baik kepada pesakit yang gagal mencapai tahap glukosa yang optima dengan 
kombinasi metformin dan sulphonilureas. Data mengenai efikasi, keselamatan serta 
keberkesanan kos di dalam penambahan agen ke tiga kepada pesakit yang gagal 
mencapai tahap glukosa yang maksima masih kurang. 
XI 
Objektif 
Objektif kajian ini adalah untuk menentukan efikasi, keselamatan dan keberkesanan 
kos dalam penambahan rosiglitazon kepada pesakit diabetes yang tidak mencapai tahap 
glukosa yang optima dengan maksima dos sulphonilureas dan metformin. 
Kaedah kajian 
Ini adalah kajian rawak secara terbuka. Pesakit yang gagal mencapai kawalan glukosa 
optima dengan kombinasi metformin dan sulfonilureas serta menolak rawatan insulin 
dibahagikan secara rawak kepada kumpulan rawatan dan kumpulan kawalan. 
Kumpulan rawatan menerima tambahan rosiglitazone 4 mg sekali sehari untuk 
jangkamasa 6 bulan manakala kumpulan kawalan mengekalkan metformin dan 
sulphonylureas dengan dos maksima. Profil paras HbA 1 c, paras glukosa berpuasa, 
profil kolesterol (TC, LDL dan HDL) diambil pada hari permulaan dan pada 6 bulan 
selepas randomisasi. 
Keputusan 
Sejumlah 75 pesakit diabetes terlibat di dalam kajian ini. Di dapati penurunan paras 
HbA1c ( 9.61 ± 1.37% kepada 8.20 ± 1.87%; p < 0.001 ) dan paras glukosa berpuasa 
( 9.6 ± 3.69 mmol/1 kepada 7.93 ± 3.46mmol/L ; p= 0.002 ) di dalam kumpulan 
rawatan selepas 6 bulan adalah signifikan. Di dalam kumpulan kawalan, di dapati 
penambahan paras HbA1c adalah signifikan ( 9.75 ± 1.33% kepada 10.06 ± 1.77%; p 
= 0.023 ) tetapi tiada perubahan signifikan di dalam paras glukosa berpuasa ( 10.81 ± 
3.38 mmol/L kepada 10.48 ± 3.29 mmol/L; p = 0.95) selepas tempoh 6 bulan. Tahap 
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penurunan HbA 1 c dan tahap glukosa berpuasa adalah lebih ketara dan signifikan di 
dalam kumpulan rawatan berbanding kumpulan kawalan , masing - masing - 1.3 7 % 
vs + 1.70% dan - 0.24 mmol/L vs + 0.41 mmol/L. Dua puluh Iapan peratus pesakit 
( 28 %, p< 0.001 ) ( 11/ 40) di dalam kumpulan rawatan mencapai HbA1c < 7% dan 
tiada pesakit di dalam kumpulan kawalan. Untuk tahap glukosa, 51 % ( p < 0. 001) ( 
19/ 3 7 ) pesakit di dalam kumpulan rawatan mencapai tahap glukosa < 7 mmol/L 
berbanding kumpulan kawalan, hanya 12 % ( 3/ 25 ) pesakit mencapai tahap glukosa < 
7 mmol/L selepas tempoh 6 bulan. Tiada perbezaan yang signifikan di dalam profil 
kolesterol pada ke dua - dua kumpulan dalam tempoh 6 bulan. 
Untuk setiap pertambahan tahap HbAlc > I %, di dapati 13.3 kali peluang untuk 
mencapai tahap HbA1c yang lebih baik (OR 13.3, adjusted 17 ). Nisbah keberkesanan 
kos di antara ke dua- dua kumpulan adalah tidak signifikan ( z = -0.79, p = 0.43 ). 
Kesimpulan 
Penambahan rosiglitazon membaiki tahap glukosa, hila dibandingkan dengan pesakit di 
dalam kumpulan kawalan, membolehkan lebih pesakit mencapai HbA 1 c < 7 % dengan 
penurunan HbA I c yang lebih signifikan. Penambahan rosiglitazon kepada pesakit yang 
telah pun mendapat metformin dan sulphonilureas maksima dos adalah berefikasi 
tetapi tidak ada keberkesanan kos. 
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ABSTRACT 
COMBINATION THERAPY FOR OPTIMUM GL YCAEMIC CONTROL: A 
RANDOMIZED OPEN LABEL TRIAL COMPARING ROSIGLITAZONE 
WITH COMBINATION SULPHONYLUREAS AND METFORMIN TABLETS 
IN TYPE 2 DIABETES MELLITUS 
Background 
As it is often difficult to achieve and maintain glycaemic goals, multiple drug therapy 
is eventually required in most patients. Combination therapy, involving an insulin 
secretagogue and an insulin sensitizer, can address the metabolic effect of this disease. 
The use of two sensitizers with different but complementary mechanisms of action may 
provide additional glucose control. The addition of thiazolidinedione may Improve 
glycaemic control in patients who failed to achieve glycaemic control with a 
combination of sulphonylureas and metformin. There is scarce data on efficacy, safety 
and cost effectiveness of adding third agent to patients who failed to achieve glycaemic 
control on maximum combination therapy. 
Objectives 
To determine the efficacy, safety and cost effectiveness of adding Rosiglitazone to 
patients with type 2 diabetes mellitus on maximum dose of sulphonylureas and 
metformin who had not achieved glycaemic control 
XIV 
Research design and methodology 
This was a randomized, open label study. The subjects with T2DM who refused insulin 
therapy were randomized into treatment group and control group. The treatment group 
received adding a dose of rosiglitazone 4 mg once daily for 6 months while the control 
group was maintained on maximum dose of metformin and sulphonylureas. HbAlc, 
FBS, Total Cholesterol, LDL and HDL were taken at baseline and at 6 month. 
Results 
A total of 75 diabetic patients were included in this study. There was significant 
reduction in HbAlc ( 9.61 ± 1.37% to 8.20 ± 1.87% ; p < 0.001 ) and FBS ( 9.6 ± 
3.69 mmoliL to 7.93 ± 3.46mmol/L; p = 0.002) in treatment group after 6 months of 
therapy. However, in control group, there was a significant increased in HbAlc (9.75 
± 1.33 % to 10.06 ± 1.77%; p = 0.023) but no significant change in FBS (10.81 ± 
3.38mmol/L to 10.48 ± 3.29 mmoliL ; p = 0.95) at 6 months. There was greater 
reduction in HbA 1 c level and FBS in treatment group compared to control group - 1.3 7 
% vs + 1. 70 % and - 0.24 % vs + 0.41 % respectively. Twenty eight percent (28 % ; 
p < 0.001) (11 I 40) of patients ofthe treatment group achieved HbA1c < 7% while no 
one in control group achieved this target. For FBS, 51 % ( p < 0.001) (19 I 37) of 
patients in the treatment group achieved FBS < 7mmol/l compared with the control 
XV 
group, only 12 % (3 I 25) of patients achieved FBS < 7 mmol/1 at 6 months. There were 
no significant changes in lipid profiles at 6 months in both groups. 
In addition, for every improvement of 1 o/o HbA1c, there was 13.3 times better chance 
in improvement of HbA1c (OR 13.3, adjusted 17 ). The cost effectiveness (CE) ratio 
between the treatment and the control group was not significant (z =- 0.79, p= 0.43) 
Conclusion 
The addition of rosiglitazone improves glycaemic control, when compared to patients 
in control group, allowing more patients to achieve HbA1c < 7 % with greater 
reduction of HbA 1 c. In addition, adding rosiglitazone to patients on maximum 
metformin and sulphonylureas were efficacious but not cost effective. 
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CHAPTER ONE 
CHAPTER ONE 
INTRODUCTION 
Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder characterized by 
pancreatic beta cell dysfunction and insulin resistance in the liver, skeletal muscle cell 
and adipose tissue (DeFronzo, 1999). It is increasing in frequency such that it is now 
considered as a worldwide epidemic. Approximately 100 million people worldwide were 
reported to have the disease in 1994, and this figure is expected to more than double to 
215 million by the year 201 0 ( Zimmet et a/, 2001 ). The therapeutic goals are to return 
glycemic control to normal and prevent emergence of long-term complications. 
1.1 Diagnosis 
Diabetes mellitus is diagnosed on the basis of WHO recommendations from 1999, 
incorporating both fasting and 2-h after glucose load (75 g) criteria into a practicable 
diagnostic classification that should now be used (table 1.1 ). Conditions that predispose 
to overt diabetes, including impaired fasting glucose and impaired glucose tolerance are 
not merely of academic interest, since, unless treated, about 7% of people with these 
problems will progress to overt diabetes every year. (Tuomilehto et a/, 2005) 
Furthermore, impaired glucose tolerance itself carries an increased risk of macrovascular 
disease (DECODE Study Group, 1999). 
1 
Table 1.1. Diagnostic criteria of diabetes mellitus and other categories of 
hyperglycaemia 
Glucose concentration in venous plasma (mmol/L) 
Diabetes mellitus Fasting 2:: 7.0 or 2 h post glucose load 11.1 
Impaired glucose tolerance Fasting(ifmeasured )<7.0 and 2 h post glucose 
load 2:: 7.8 and< 11.1 
Impaired fasting glucose Fasting 2:: 6.1 and< 7.0 and 2 h post-glucose load 
( if measured) < 7. 8 
Glucose load= 75 g glucose orally 
1.2 Pathophysiology of type 2 diabetes 
To understand the cellular and molecular mechanisms responsible for T2DM it is 
necessary to conceptualize the framework within which glycaemia is controlled. Insulin 
is the key hormone for regulation of blood glucose and, generally, normoglycaemia is 
maintained by the balanced interplay between insulin action and insulin secretion. 
Importantly, the normal pancreatic beta cell can adapt to changes in insulin action i.e., a 
decrease in insulin action is accompanied by upregulation of insulin secretion (and vice 
versa). Figure 1.2. illustrates the curvilinear relation between normal beta cell function 
and insulin sensitivity (Bergman , 1989). Deviation from this hyperbola, such as in the 
patients with impaired glucose tolerance and T2DM, occurs when beta cell function is 
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inadequately low for a specific degree of insulin sensitivity. Thus, beta cell dysfunction 
is a critical component in the pathogenesis ofT2DM. This concept has been verified not 
only in cross-sectional studies but also longitudinally in Pima Indians progressing from 
normal to impaired glucose tolerance to T2DM {Weyer eta/, 1999). However, not only 
deviation from but also progression along the hyperbola affects glycaemia. When insulin 
action decreases (as with increasing obesity) the system usually compensates by 
increasing beta cell function. However, at the same time, concentrations of blood 
glucose at fasting and 2 h after glucose load will increase mildly. (Stumvoll eta/, 2003), 
This increase may be small, but over time becomes damaging because of glucose 
toxicity, and in itself a cause for beta cell dysfunction. Thus, even with (theoretically) 
unlimited beta cell reserve, insulin resistance paves the way for hyperglycaemia and 
T2DM. 
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Figure 1.2. Hyperbolic relation between insulin sensitivity and beta cell function. In people 
with normal glucose tolerance ( NGT) a quasi hyperbolic- relation exists between cell 
function and insulin sensitivity. With deviation from this hyperbola, deterioration of 
glucose tolerance ( impaired glucose tolerance [ IGT]) and T2DM occurs. Adapted from 
Stumvoll M, Barry JG, Timon W ( 2005) 
1.2.1. Insulin resistance 
Insulin resistance is said to be present when the biological effects of insulin are less than 
expected for both glucose disposal in skeletal muscle and suppression of endogenous 
glucose production primarily in the liver ( Dinneen et al, 1992 ) In the fasting state, 
however, muscle accounts for only a small proportion of glucose disposal (less than 
20%) whereas endogenous g lucose production is responsible for all the glucose entering 
the plasma. Endogenous glucose production is accelerated in patients with type 2 
diabetes or impaired fasting glucose. (Weyer et al, 1999: Meyer et al, 1998 ) Because 
this increase occurs in the presence of hyperinsulinaemia, at least in the early and 
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intermediate disease stages, hepatic insulin resistance ts the driving force of 
hyperglycaemia of T2DM 
1.2.2. Potential causes of beta cell dysfunction in Type 2 diabetes. 
1 ) Reversible metabolic abnormalities 
a ) Glucotoxicity 
Glucose toxicity is a concept that associates beta cell desensitization to glucose with 
increase blood glucose concentration ( Robertson eta/, 1994; Yki-Jarvinen, 1992 ). This 
has been demonstrated with in vitro and in vivo animal research ( Weir et a/, 1983; 
Trend et al, 1992 ) Lowering serum glucose levels in T2DM or impaired glucose 
tolerance can increase their acute response to glucose ( . Mott et a/, 1993 ). Chronic 
hyperglycaemia may deplete insulin secretory granules from beta cells, leaving less 
insulin ready for release in response to new glucose stimulus. Lowering glucose levels 
allow regranulation of beta cells, and thus, better insulin response. 
b) Lipotoxicity 
Lipotoxicity has deleterious effects on beta cells of accumulated fatty acids and their 
metabolic products that are observed among individuals with insulin resistance, glucose 
intolerance and T2DM. Evidence leading to this hypothesis includes data from in vitro 
and in vivo animal studies ( Zhou et al, 1998; Unger et al, 1995, 2001). Fluctuations of 
free fatty acid levels are necessary for normal beta cell function but prolonged increase 
in their levels have a negative impact on the conversion of pro insulin to insulin and thus 
on insulin secretion ( Zhou et al, 1995 ; Grill et al, 1994, Sako et al, 1990) . The 
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extent to which lipotoxicity contributes to progressive beta cell failure that leads to 
diabetes is still unknown. 
2) Reduction of beta cell mass 
A reduction in beta cell mass has been observed in people with T2DM ( Kloppel eta/, 
1985 ; Janssen eta/ , 2003 ) and impaired glucose tolerance compared with people who 
are equally obese but have normal glucose levels. The exact cause is unknown and 
probably complex. It may relate to glucose or lipid toxicity whereby programme cell 
death ( apoptosis ) occurs in hostile metabolic and biochemical environment ( Efanova 
et a/, 1998 ) . In vitro and vivo animal studies have highlighted possible causes of 
reduced beta cell mass : impaired beta cell function, glucose intolerance and rising 
hyperglycaemia in conjunction with amyloid deposits and toxic amyloid fibrils ( 
Jansson et a/, 1999 ; Lorenzo et a/, 1994 ). Interestingly, predisposing characteristic 
found in patients with T2DM are also observed in animal models for amyloid 
disposition, namely high fat diet and oestrogen depletion ( Kahn et al, 2000; Manson et 
a!, 1992; Marshall et al, 1992 ) . 
Other potential causes are hormonal changes which includes inadequate in cretin action 
and increased glucagons secretion and genetic abnormalities of beta cell proteins ( 
glukokinase, insulin receptor, IRS - 1, HNF - 4 a ). 
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2.0 The importance of Glycemic Control 
It has never been clearer that hyperglycemia, as assessed by the hemoglobin A 1 c 
(HbA 1 c) measurement, is the prime cause of diabetic microvascular complications 
(retinopathy, nephropathy, and neuropathy) and plays a role in the premature and 
accelerated development of diabetic macro vascular complications (coronary artery 
disease, cerebrovascular disease, and peripheral vascular disease). The Diabetes Control 
and Complications Trial (DCCT) showed that with a 2% difference (9% vs. 7%) in the 
HbAlc level there was a 63% decrease in development of retinopathy, a 54% decrease 
in the development of nephropathy, a 60% decrease in the development of neuropathy, 
and a 41% decrease in the development of macrovascular disease in type 1 diabetic 
patients; furthermore, the incidence of these complications was low if the HbA 1 c level 
was maintained at 7%. In addition, the DCCT showed that if the HbA 1 c level was above 
8%, the rate of development of microvascular complications accelerated dramatically; as 
a result, the ADA recommended that intensification of therapy was required if the 
HbA1c level was above 8% ( DCCT, 1993 ). 
The Kumamoto study demonstrated an association between glycemic control and 
chronic diabetic complications in T2DM. They used thin, insulin-requiring, Japanese 
type 2 patients and used a protocol similar to that used by the DCCT (Ohkubo et a/, 
1995 ). As expected, the outcomes were similar, with a 2.0% difference in HbA1c level 
being associated with a 69% decrease in retinopathy and a 70% decrease in nephropathy 
The increasing use of HbA 1 c to monitor long-term glycemic control in diabetic patients 
is largely the result of data from the DCCT and the U.K. Prospective Diabetes Study 
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showing that HbA1c is strongly correlated with adverse outcome risks (UKPDS 33, 
1998). 
3.0 Management of hyperglycaemia 
In making therapeutic choices (Figure 1.3) in the management of T2DM, the major goal 
of protecting patients from the long-term complications of the disease must be 
considered. Because insulin resistance plays a fundamental role in the pathogenesis of 
type 2 diabetes and especially its adverse cardiovascular outcomes, interventions should 
initially be aimed towards improvement in tissue insulin sensitivity. This often involves 
lifestyle intervention, with modest exercise and weight loss, which clearly reduces the 
risk of progression of impaired glucose tolerance to overt diabetes ( Diabetes Prevention 
Program Research Group , 2002: Tuomilehto et a!, 200 I ) and can improve many of the 
cardiovascular risk parameters of the metabolic syndrome. 
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Figure 1.3. Pharmacological treatment of hyperglycaemia according to site of action. 
Adapted from Stumvoll M, Barry JG, Timon W ( 2005) 
1.4.1 Thiazolidinediones 
Drugs that enhance insulin sensitivity are primarily those of the thiazolidinedione class, 
which not only reduce glycaemia, but also enhance vascular function and ameliorate the 
dyslipidaemia and inflammatory milieu of T2DM ( Yki-Jarvinen et al , 2004 ) 
Thiazolidinediones primarily activate PP AR y receptors in adipose tissue and alter 
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adipose metabolism and distribution. The redistribution of tissue triglyceride from 
visceral stores reduces levels of circulating fatty acid apparently by sequestration in a 
less lipolytic subcutaneous compartment.( Yki- Jarvinen et a/, 2004 ). 
Thiazolidinediones also reduce circulating concentrations of pro-inflammatory cytokines 
that promote insulin resistance ( eg, TNF a and interleukin 6) and at the same time 
increase concentrations of adiponectin, which has insulin-sensitising and anti-
inflammatory properties. The multiple effects of thiazolidinediones on adipose tissue 
metabolism and cross-talk of these signals with liver and skeletal muscle, as well as 
pancreatic beta cells and the vascular endothelium, might account for the enhancement 
of insulin action and improvement in insulin secretion with these agents, as well as 
several beneficial effects on vascular function ( Meriden et a/, 2004 ). The renal and 
vascular benefits of thiazolidinediones have been demonstrated in controlled studies, for 
example, showing significant improvement in albumin excretion above that observed 
with a similar degree of glycaemic lowering with sulfonylureas. ( Einhorn et a/, 2004 ) 
Unlike metformin, the thiazolidinediones can be used in patients with reduced renal 
function, and they are better tolerated without significant gastrointestinal side effects. 
A major adverse effect associated with clinical use of the thiazolidinediones is weight 
gain, which seems to be coupled to the effects of the drugs on adipose cell 
differentiation and triglyceride storage. Fluid retention is also linked to the PP AR y-
agonist activity of the thiazolidinediones, leading to peripheral oedema and a mild 
haemodilution in some patients. Fortunately, congestive heart failure is quite rare with 
use of thiazolidinediones, but remains a serious concern that requires caution in selection 
of patients to receive these agents ( Nesto et al, 2003). 
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In addition, there is also increased adiposity, although some studies suggest relative 
sparing of visceral fat. All thiazolidinediones cause a slight increase in low-density 
lipoprotein (LDL) levels and a substantial increase in high-density lipoprotein (HDL) 
levels. Thus, the LDL-to-HDL ratio actually decreases. There is also a slight lowering of 
blood pressure. 
Unlike other antidiabetic agents, the thiazolidinediones have a very slow onset of action. 
Although effects begin within 2 weeks, the maximal benefit of treatment is not seen for 
about 3 months ( Meriden et a/, 2004 ) When combined with insulin or with 
sulfonylureas, the onset and peak effect occur more rapidly, perhaps within 4 weeks 
( Horton eta/, 1998; Fonseca eta/, 2000 ). 
1.4.2 Metformin 
Metformin is a highly effective antihyperglycaemic drug that works independently of the 
pancreas, sparing insulin. It decreases hepatic glucose output and has been shown to 
have a beneficial effect on cardiovascular outcomes .( Bailey et a/, 1996 : Cusi et a/, 
1996, Mamputu eta/, 2003 ). Metformin has less robust effects on insulin resistance, 
inflammatory markers, and vascular function compared with the thiazolidinediones, but 
its benefit in abrogating some of the weight gain commonly observed with insulin-
sensitisers and insulin secretion enhancers adds important value to this drug. 
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1.4.3 Sulfonylurea derivatives 
As inadequate beta cell insulin secretion is fundamental to the development of 
hyperglycaemia in diabetes, insulin secretion enhancers also play an important role in 
control of blood glucose. Sulfonylurea derivatives act by closing pancreatic cell 
potassium channels, which leads to enhanced insulin secretion. The results of the UK 
Prospective Diabetes Study showed a clear risk reduction for the occurrence of 
microvascular complications by the use of sulfonylurea derivatives, while the risk 
reduction ofmacrovascular disease was around 16% ( UKPDS 33, 1998). The mode of 
action of sulfonylurea derivatives implies that they also act at low concentrations of 
plasma glucose, which explains the potential of (occasionally severe) hypo glycaemia. 
1.4.4 Combination drug therapy 
One of the major lessons of the UKPDS was to demonstrate that treatment of non-
insulin-dependent diabetes with a single agent is not sufficient to attain the target goal of 
therapy. Although the level of attained benefit in the pharmacologically treated group as 
compared with the diet-treated group was 0.9%, there was still a deterioration over 10 
years to 7.9%, with no advantage for any one pharmacologic group (Turner eta/, 1999) 
Clearly, these levels are far from the target of normal HbA 1 c. 
No one drug is capable of normalizing HbA1c in the vast majority of patients. This is 
particularly true in view of the progressive deterioration in control demonstrated in 
monotherapy in the UKPDS. However, each class of drugs shows additive benefits when 
added to other classes. The most common combination therapies are a SU plus 
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metformin (UKPDS 33, 1998), a SU plus TZD ( for persons with insulin resistance ) ( 
Einhorn et a/, 2004; Fonseca et a/, 2000 ) and metformin plus TZD ( Fonseca et a/, 
2000, Einhorn et a/, 2004 ). Oral agents from different classes have an additive effect· 
' 
each consecutive oral agent achieves an additional 1 - 2 % reduction in HbAlc level 
relative to monotherapy ( Inzucchi et a/, 2002 ). 
For most patients with T2DM, the combination of a TZD and metformin will reduce 
hyperglycemia, hyperinsulinemia, and insulin resistance, preserve p cell function, and 
improve other components of the metabolic syndrome (e.g., dyslipidemia, hypertension, 
central obesity). These combination also has been shown to significantly reduce fasting 
plasma-glucose concentrations and HbAlc compared with metformin alone (Fonseca et 
a/ 2000 ·Gomez Perez eta/, 2002 ).This derives from actions ofmetformin on the liver 
' ' ' 
resulting in reduced hepatic glucose production, and those of the TZD on the adipocyes, 
resulting in increased peripheral glucose disposal and whole body insulin sensitivity. 
Furthermore, there is evidence that the combination of a TZD with metformin attenuates 
the weight gain associated with TZD monotherapy (Fonseca eta/, 2000; Gomez Perez 
et a/, 2002 ). By initiating combination therapy early in the course of the disease, it is 
hoped that many of the vascular complications associated with insulin resistance and 
T2DM can be delayed or avoided. 
On the other hand, even the combination of oral agents may fail to sustain desirable 
glycemic control because of declining circulating insulin levels secondary to progressive 
beta cell dysfunction. Clinical studies also showed that diabetes treatment with insulin 
sensitizers does not fully correct insulin sensitivity nor restore adequate glucose 
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tolerance 1n all cases, implying genetic and I or environmental factors may also 
influence the individual response to these drugs. Masugi Z in their vitro studies 
suggested that genetic variants of the PP AR y gene may influence the drug efficacy of 
TZD ( Masugi et al, 1999). At this stage of the disease, initiation of insulin is required, 
either as monotherapy or as an adjunct to oral agents to attain and maintain glycemic 
control. 
1.5 The role of insulin 
The natural history of T2DM is characterized by progressive impairment of insulin 
secretion, paralleled by progressive deterioration of glycaemic control. Typically, the 
association of a sulphonylurea to a pre existing insulin sensitizer is intended to address 
such metabolic imbalance. Eventually, 'secondary failure ' occurs, and the patient is 
shifted to insulin therapy ( Francesco et a/, 2005 ). However, whether sulphonylureas 
may accelerate the loss of pancreatic secretory capacity, by causing beta cell apoptosis, 
has not been addressed in clinical studies. Early insulin administration in recently 
diagnosed diabetic patients has been proposed as an alternative approach that may 
provide some kind of 'beta cell rest' and I or protection from apoptotic stimuli 
(Alvarrsson eta/, 2003 ). 
The most compelling argument for the early use of insulin is the lack of any alternative 
when glycaemic targets are no longer attained with oral antidiabetic agents. It must be 
noted that intensive therapy in the UKPDS was beneficial overall despite an increase in 
weight gain, and thus it is inappropriate in most cases to withhold insulin because of this 
anticipated side effects ( UKPDS 33 , 1998 ). The benefits of an intensive strategy in 
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microvascular complications were demonstrated clearly in UKPDS, although the benefit 
of macrovascular complications failed to reach significance. Insulin therapy did, 
however, yield a large mortality benefit in the context of acute myocardial infarction in 
The Diabetes Mellitus Insulin- Glucose Infusion in Acute Myocardial Infarction ( 
DIGAMI ) trial, which is, at the very least, strongly suggestive of a beneficial effect on 
cardiovascular status in the long term (Malmberg, DIGAMI, 1997) 
1.5.1 Why insulin therapy delayed in persons with type 2 diabetes? 
Persons with T2DM may favor the postponement of insulin therapy, usually because of 
concerns about associated weight gain, insulin resistance and fear of injection. Most 
clinicians will have known patients with whom insulin therapy appeared to lead to 
massive weight gain without significant improvements in glycaemic control , and early 
conversion to insulin is not a panacea for the insulin resistant patient. 
Survey from cross- national Diabetes Attitudes, Wishes and Needs (DAWN) study 
which identify correlates of attitudes toward insulin therapy among patients with T2DM 
and provider showed that their attitude differ significantly across countries, controlling 
for individuals characteristics. In this survey, patients rate the clinical efficacy of insulin 
as low and would blame themselves if they had to start insulin therapy. Self-blame is 
significantly lower among those who have better diet and exercise adherence and less 
diabetes-related distress. Patients who are not managing their diabetes well (poor 
perceived control, more complications, and diabetes-related distress) are significantly 
more likely to see insulin therapy as potentially beneficial. Most nurses and general 
practitioners (50-55%) delay insulin therapy until absolutely necessary, but specialists 
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and opinion leaders are less likely to do so. Delay of insulin therapy is significantly less 
likely when physicians and nurses see their patients as more adherent to medication or 
appointment regimens, view insulin as more efficacious, and when they are less likely to 
delay oral diabetes medications. 
Health providers should be aware of the importance in early introduction to insulin 
therapy. They should educate and motivate their patients regarding the need to start 
insulin early. Survey from DAWN also noted that diabetes related worries were common 
among patients ( 41 %) and providers recognized these worries but lack of resources 
( skill, time, adequate referral centre ). These poor psychological well-being affected 
diabetic self care. These issue need to be address to achieve optimum diabetic 
management. 
Several studies have shown that improving glycaemic control with insulin therapy has 
an improving effect on underlying insulin resistance, contradicting concerns that greater 
hyperinsulinaemia would increase insulin resistance (Riddle, 2002 ; Garvey et a/, 1985 ). 
Additionally, conversion to insulin is usually preceeded by a period of hyperglycaemia 
when body weight is lost as a consequence of glycosuria ( Makkimatila et al, 1999 ). 
Although insulin reverses this process, it does not in itself cause significant weight gain ( 
Larger eta/, 2001 ). While this fact may be of little comfort to those patients who find 
themselves getting heavier, it does indicate the beneficial effect of early introduction of 
insulin in treating diabetes. 
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1.6 Cost effectiveness analysis ( CEA ) 
Cost effective analysis is a method comparing the health outcomes ( effectiveness ) and 
the net costs from a program or an intervention against other alternatives with similar 
health outcomes ( Cariere et a/, 2001 ). It measures health outcomes in real terms, such 
as mortality, disability or quality of life. The net costs from a program or intervention 
are the costs for providing the program and for committing the resources for treatments 
after subtracting the non- health benefits from the program measured in monetary terms. 
Decision makers would choose a program that is most effective and least expensive. 
Carrie et al in their article summarized CEA in several steps. 
The first step is to state the program or the intervention to be evaluated. Such detailed 
questions as what are the objectives; what experimental designs are being applied to the 
program should be answered in advanced. The perspective from which the analysis is 
being conducted is an important consideration. The costs savings or benefit may have 
different values from different perspectives, as accost from one perspective may be a 
benefit from another perspectives. In the second step, all resources of relevant costs and 
benefits have to be identified in real terms. The net benefits or benefit- to- cost ratios is 
calculated, based on which choice of the intervention with optimum value of net benefit 
or benefit to cost ratio is followed. Investigators would like to include all costs and 
benefits, direct cost and benefits, indirect costs and benefits and intangible benefits. 
In the third step, benefits are identified and valued. The results from step 2 are adjusted 
by a discount rate because the monetary values at present depreciate over time. It also 
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adjusts for the health outcomes in some circumstances. The adjustment for health 
outcomes depends on what the health outcomes are and how the values for health 
outcomes change with time. The interpretation of the results from CEA will depend on 
incremental cost effectiveness ratio defined by the additional cost of an alternative 
relative to its additional effectiveness, or the original net costs and effectiveness. 
1.6.1 The role and use of outcomes assessments 
Outcomes research is the field of study describing the ultimate ( final ) health events that 
occur as a result of a condition or its treatment ( Kozma eta!, 1993 ). Stated differently, 
outcomes research is the process by which health care interventions are evaluated in 
order to measure the extent to which a goal of therapy can be reached. One classic list of 
outcome measures compromised the five Ds ( Johnson et a!, 1996) : death, disease, 
disability, discomfort and dissatisfaction. Several of these D s reflect a patient QoL ( 
quality of life). Addition of the sixth D ( dollars ) produces a comprehensive list of 
measures to assess outcomes of medical interventions. 
The type of outcomes can be grouped into three categories : 
• Clinical based outcomes 
• Patient based outcomes - Patient QoL is important criterion in determining the 
success of medical intervention. 
• Cost based I economic outcomes- include items such as prescription medications, 
physician visits, laboratory tests, adverse events and treatment failures. 
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1.6.2 Applications for outcome research 
Outcomes data are useful in evaluating the effectiveness of health care interventions. 
Adding patient - centered and economic outcome to the traditional clinical outcomes 
provides a comprehensive assessment of treatment and service( A Grizzle et a!, 200 I). 
Outcome data may also be used to support and understand research conclusions. 
Formulary committees are beginning to incorporate outcome measures ( i.e. cost 
effectiveness and QoL ) in their decision making process. With third party payers 
assuming more authority for drug purchasers , pharmaceutical companies now need to 
provide additional evidence of drug benefits, including cost effectiveness ratios and 
improvement in QoL compared with competitors. Outcome research, therefore, becomes 
an important aspect of new product development, as pharmaceutical companies need to 
demonstrate more than clinical benefits. 
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CHAPTER TWO 
CHAPTER TWO 
OBJECTIVES 
2.1 General Objectives 
2.1.1. To determine the efficacy, safety and cost effectiveness of adding Rosiglitazone to 
patients with type 2 diabetes mellitus on maximum dose of Glibenclamide I Gliclazide 
and Metformin who had not achieved glycaemic control 
2.2 Specific Objectives 
2.2.1. To assess the reduction of HbAlc and fasting plasma glucose in patient treated 
with Sulphonylureas and Metformin combined with Rosiglitazone after 6 months 
duration 
2.2.2. To compare the reduction of HbA1c between the group patients treated with 
Sulphonylureas and Metformin combined with Rosiglitazone and Sulphonylureas plus 
Metformin alone. 
2.2.3 To establish incidence of hypoglycaemia in the group patient treated with 
Sulphonylureas and Metformin combined with Rosiglitazone. 
2.2.4. To determine the cost effectiveness of adding Rosiglitazone 1n treating 
uncontrolled type 2 diabetes mellitus with maximum combination of Sulphonylureas and 
Metformin. 
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CHAPTER THREE 
CHAPTER THREE 
METHODOLOGY 
3.1 Study area 
This study was carried out in Hospital University Science Malaysia ( HUSM) which is a 
teaching hospital situated in Kubang Kerian, under Kota Bharu district. It functions as a 
tertiary referral centre for various disciplines and departments. This includes patients 
from the state of Kelantan and some parts of Terengganu. The study was approved by 
the Research and Ethics Committee, University Sains Malaysia. 
3.2 Study design 
The study was a randomized open label trial of optimal glycaemic control in patients on 
combination therapy with Rosiglitazone. The study was conducted between December 
2004 until July 2005. 
3.3 Source population 
A total of 88 patients were selected, all of whom were on regular follow up at the 
diabetic clinic in hospital University Sains Malaysia, Kubang Kerian. 
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Inclusion and exclusion criteria 
3.3.1 Inclusion criteria 
1. Able to sign informed consent 
2. Patients with type 2 diabetes mellitus 
3. Age between 20 to 78 years old 
4. BMI 2:: 23 and ~ 40 kg/m2 
5. Inadequate control of diabetes mellitus with HbA1c levels > 7.0% and~ 12.0% 
6. On maximwn dose of Glibenclamide ( 20 mg daily ) or Gliclazide ( 320 mg 
daily ) and Metformin ( 2000 mg daily ) or Metformin SR ( 1700 mg daily ) 
7. Refused insulin therapy 
3.3.2 Exclusion criteria 
1. Use of other hypoglycaemic agents other than stable doses of Metformin/ 
Sulphonylureas or Thiazolidinediones within 8 weeks before screening 
2. Renal dysfunction ( serum creatinine level> 1.5 mg/dl for men or> 1.4 mg/dl 
for women 
3 · Abnormal liver function ( serwn AL T , AST or total bilirubin level > twice the 
upper limit of normal 
4. Anaemia ( Hb < 10 g % or hemoglobinopathies ( thalasaemia ) at start 
5. Clinically substantial cardiac, respiratory, congestive cardiac failure or 
psychiatric illness. 
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3.4 Sampling frame 
All patients with Type 2 diabetes mellitus receiving treatment at hospital USM, Kubang 
Kerian 
3.5 Sampling method 
Before randomization, a complete and thorough medical and social history was recorded 
from the patient. Exclusion study criteria were highlighted and inclusion study criteria 
were satisfied. Patients who fulfilled the inclusion criteria were given card numbers. 
The even numbers were recruited in the control group and the odd numbers were 
recruited in the treatment group. The control group was continued with maximum doses 
of sulphonylureas and metformin tablets. The treatment group was given rosiglitazone 4 
mg once daily while maintaining the maximum dose of sulphonylureas and metformin. 
3.6 Data collection 
The data that were collected include: 
a) demographic data 
• age, sex, BMI 
b) medical history 
• duration of diabetes, complication of diabetes, treatment of diabetes 
c) blood investigations 
• HbAlc, FBS, Total cholesterol, HDL, LDL at baseline and at 24 weeks. 
Data on blood investigation were repeated at 24 weeks. 
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d) drug cost 
• the costs for metformin ( 1700 mg daily) or metformin ( 2000 gm daily) and 
glibenclamide ( 20 mg daily ) or gliclazide ( 320 mg daily) in the control group 
and the adding cost of rosiglitazone ( 4 mg daily ) were recorded at the first visit. 
The information concerning the mode of treatment was obtained from the case notes as 
well as by interviewing the subjects. 
Visits occur every 12 weeks for 24 weeks. Symptoms of side effects were asked in both 
groups on the second visit. Blood samples for the HbAlc were analyzed at the 
endocrine laboratory whereas plasma glucose and cholesterol were analyzed at the 
Chemical Pathology laboratory of Hospital University Sains Malaysia, Kubang Kerian. 
For blood glucose testing, 2.5 ml blood sample was collected in a Sodium Oxalate 
contained container. A glucose analyzer which uses the glucose oxidase was used for 
plasma glucose measurement. Blood samples for HbAlc measurement was collected in 
a plain container and analyzed using both the DiaSTATTM Hemoglobin Ale Analyzer ( 
Bio- Rad Laboratories, USA ) which is a low pressure liquid chromatography system ( 
LPLC ) and D 10 Analyzer which is a high performance liquid chromatography ( HPLC) 
, designed for the rapid and fully automated measurement of HbA 1 C. A comparison of 
DiaSTATTM and DIO gave correlation of 0.99. For TG and TC profile measurement, 
2.5 ml blood sample was collected into EDT A contained container. The method used 
was Enzymatic method. The sample was analysed using Roche/ Hitachi analyser. The 
LDL cholesterol was by calculation (shown below) 
In mmol/L: 
LDL Cholesterol = Total Cholesterol - TG/ 2.2- HDL Cholesterol ( mmol/L ) 
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